<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nineteen patients with high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) received fludarabine, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, granulocyte-colony stimulating factor (G-CSF), and <z:chebi fb="0" ids="42068">idarubicin</z:chebi> chemotherapy (de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, nine; relapsed/refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, seven; <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e>, three) </plain></SENT>
<SENT sid="1" pm="."><plain>Median age was 44 years and median disease duration 10 months </plain></SENT>
<SENT sid="2" pm="."><plain>16/19 (84%) patients had abnormal cytogenetics with seven (37%) harbouring abnormalities of chromosome 7 </plain></SENT>
<SENT sid="3" pm="."><plain>18/19 (94.7%) patients responded to FLAG-<z:chebi fb="0" ids="42068">idarubicin</z:chebi> with 12 (63%) achieving complete remission (CR) (&lt; 5% blasts and <z:mpath ids='MPATH_458'>normal</z:mpath> cytogenetics) </plain></SENT>
<SENT sid="4" pm="."><plain>7/9 (78%) patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> achieved CR compared to 5/10 (50%) with alternative diagnoses </plain></SENT>
<SENT sid="5" pm="."><plain>Response was associated with age &lt; 50 years, disease duration &lt; 3 months, and cytogenetics other than abnormalities of chromosome 7 </plain></SENT>
<SENT sid="6" pm="."><plain>Haemopoietic regeneration was rapid in most patients and there were no toxic <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Nine patients received a second course of chemotherapy, three have proceeded to allogeneic bone marrow transplant and three to autologous blood stem cell/bone marrow transplantation </plain></SENT>
<SENT sid="8" pm="."><plain>Follow-up is short (median 10 months) </plain></SENT>
<SENT sid="9" pm="."><plain>12/19 (63%) patients remain alive and 5/12 (42%) have relapsed at a median 5 months following CR achievement </plain></SENT>
<SENT sid="10" pm="."><plain>FLAG-<z:chebi fb="0" ids="42068">idarubicin</z:chebi> was well tolerated </plain></SENT>
<SENT sid="11" pm="."><plain>High rates of morphological and cytogenetic remission, especially in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, offer a window of opportunity for assessment of autologous BMT in this group of diseases where no treatment except alloBMT has led to prolongation of survival </plain></SENT>
</text></document>